Gilead Sciences (NASDAQ:GILD) shares ticked up after the company raised full year sales and profit outlook, helped by growing demand for its HIV products.
The California based biotech raised its full year adjusted profit to a range between $7.95 per share and $8.25 per share from a previous range between $7.70 per share and $8.10 per share. Consensus for the year by analysts is of $8 per share.
\It also lifted its 2025 net product sales outlook to the range between $28.30B and $28.70B, above the prior range between $28.20B and $28.60B versus consensus of 28.73B.
The company reported Q2 revenue of $7.08B, beating consensus of 6.96B. It recorded adjusted profit of $2.01 per share, above analysts' estimate of $1.96 per share.
"Our strong growth this quarter was driven by Biktarvy, Descovy, Trodelvy and Livdelzi, reflecting the diversity of our portfolio," CEO Daniel O’Day stated.
Gilead's HIV product sales rose 7% to $5.1B in Q2, compared to the same period in 2024.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.